BioCentury | Nov 5, 2020
Deals

Merck adds ROR1 to its pipeline, rewards VelosBio’s investors with $2.8B takeout

Although VelosBio appeared to be heading down the path to an IPO, the oncology company has instead accepted a $2.8 billion takeout offer from Merck now that the biotech’s antibody-drug conjugate has shown signs of...
BioCentury | Oct 29, 2020
Product Development

Flagship’s Senda builds on Kintai’s microbe-mimicking pipeline with plant and bacteria-based delivery modalities

Flagship’s latest portfolio company mash-up brings together technologies that take advantage of microbial and plant biology to treat human disease. Senda Biosciences rolls together four companies founded...
BioCentury | Oct 3, 2020
Product Development

How virtual drug launches could change the biopharma industry

The move to digital launch models that emerged during the pandemic is likely to permanently change the way biopharma companies approach new drug sales, with knock-on effects for partnering trends and pipeline...
BioCentury | Jul 28, 2020
Politics, Policy & Law

Biopharma industry accelerates attacks on Trump

Last week the White House invited Pfizer Chairman and CEO Albert Bourla to join a group of his peers at the White House Tuesday to discuss drug pricing with President Donald Trump. Instead of traveling...
BioCentury | Jun 19, 2020
Product Development

T cell tests aim for broader picture of COVID-19 immunity

While the COVID-19 testing conversation has centered on assays for antiviral antibodies or the virus itself, at least two companies think T cell tests could catch patients the other methods miss. T cell tests could...
BioCentury | May 2, 2020
Deals

At the end of this crisis, the biopharma ecosystem might emerge with a better landscape

It’s not yet clear how deep the economic scars will be for biotechs from this crisis. Some will surely suffer. But VCs and pharmas see an opportunity for the industry to emerge stronger, given that...
BioCentury | Apr 11, 2020
Product Development

COVID-19 roundup: Lilly joins NIH’s adaptive trial; plus Foresee, Congress, ASCO, BMS, Otsuka, EC, Terumo-Marker

Eli Lilly’s rheumatoid arthritis drug Olumiant baricitinib has become the second treatment added to NIH’s COVID-19 master protocol, joining Gilead’s remdesivir. Separately, U.S. representatives called on FDA to ensure diagnostics are accurate, and ASCO launched...
BioCentury | Dec 10, 2019
Product Development

Leon Wang: Let China be China. The next phase in AZ’s China R&D strategy

Leon Wang believes that AstraZeneca has a chance to succeed at R&D in China because its global headquarters has learned to loosen the reins on its satellite premises. A multinational asking locals to carry out...
BioCentury | Nov 22, 2019
Finance

DigiTx focuses on data in evolving landscape of digital health investing

As one of the few digital therapeutics-focused investors, DigiTx is parsing opportunities in the rapidly expanding field by homing in on companies that use or generate patient data in innovative ways. DigiTx Partners was launched...
BioCentury | Nov 16, 2019
Product Development

Navigating IP strategies in the world of digital therapeutics

For digital therapeutics, which straddle life sciences and tech, IP may be less important to creating value than the data they generate. As biopharma companies move into the world of digital therapeutics, they will need...
Items per page:
1 - 10 of 957
BioCentury | Nov 5, 2020
Deals

Merck adds ROR1 to its pipeline, rewards VelosBio’s investors with $2.8B takeout

Although VelosBio appeared to be heading down the path to an IPO, the oncology company has instead accepted a $2.8 billion takeout offer from Merck now that the biotech’s antibody-drug conjugate has shown signs of...
BioCentury | Oct 29, 2020
Product Development

Flagship’s Senda builds on Kintai’s microbe-mimicking pipeline with plant and bacteria-based delivery modalities

Flagship’s latest portfolio company mash-up brings together technologies that take advantage of microbial and plant biology to treat human disease. Senda Biosciences rolls together four companies founded...
BioCentury | Oct 3, 2020
Product Development

How virtual drug launches could change the biopharma industry

The move to digital launch models that emerged during the pandemic is likely to permanently change the way biopharma companies approach new drug sales, with knock-on effects for partnering trends and pipeline...
BioCentury | Jul 28, 2020
Politics, Policy & Law

Biopharma industry accelerates attacks on Trump

Last week the White House invited Pfizer Chairman and CEO Albert Bourla to join a group of his peers at the White House Tuesday to discuss drug pricing with President Donald Trump. Instead of traveling...
BioCentury | Jun 19, 2020
Product Development

T cell tests aim for broader picture of COVID-19 immunity

While the COVID-19 testing conversation has centered on assays for antiviral antibodies or the virus itself, at least two companies think T cell tests could catch patients the other methods miss. T cell tests could...
BioCentury | May 2, 2020
Deals

At the end of this crisis, the biopharma ecosystem might emerge with a better landscape

It’s not yet clear how deep the economic scars will be for biotechs from this crisis. Some will surely suffer. But VCs and pharmas see an opportunity for the industry to emerge stronger, given that...
BioCentury | Apr 11, 2020
Product Development

COVID-19 roundup: Lilly joins NIH’s adaptive trial; plus Foresee, Congress, ASCO, BMS, Otsuka, EC, Terumo-Marker

Eli Lilly’s rheumatoid arthritis drug Olumiant baricitinib has become the second treatment added to NIH’s COVID-19 master protocol, joining Gilead’s remdesivir. Separately, U.S. representatives called on FDA to ensure diagnostics are accurate, and ASCO launched...
BioCentury | Dec 10, 2019
Product Development

Leon Wang: Let China be China. The next phase in AZ’s China R&D strategy

Leon Wang believes that AstraZeneca has a chance to succeed at R&D in China because its global headquarters has learned to loosen the reins on its satellite premises. A multinational asking locals to carry out...
BioCentury | Nov 22, 2019
Finance

DigiTx focuses on data in evolving landscape of digital health investing

As one of the few digital therapeutics-focused investors, DigiTx is parsing opportunities in the rapidly expanding field by homing in on companies that use or generate patient data in innovative ways. DigiTx Partners was launched...
BioCentury | Nov 16, 2019
Product Development

Navigating IP strategies in the world of digital therapeutics

For digital therapeutics, which straddle life sciences and tech, IP may be less important to creating value than the data they generate. As biopharma companies move into the world of digital therapeutics, they will need...
Items per page:
1 - 10 of 957